Top Wall Street Forecasters Revamp Omeros Price Expectations Ahead Of Q4 Earnings

Group 1 - Omeros Corporation is set to release its fourth-quarter financial results on March 31, with analysts expecting a quarterly loss of 78 cents per share, compared to a loss of 69 cents per share in the same period last year [1] - On March 21, Omeros provided an update on its ongoing Zaltenibart Phase 3 PNH clinical trial program [1] - Omeros shares increased by 4.7%, closing at $8.92 on Thursday [1] Group 2 - Needham analyst Serge Belanger maintained a Hold rating on Omeros with an accuracy rate of 68% [4] - Cantor Fitzgerald analyst Olivia Brayer reiterated a Neutral rating on Omeros, achieving an accuracy rate of 62% [4]